SCHEMBL5740503

SCHEMBL5740503

C=Cc1ccccc1S(=O)(=O)N1CCN(CC2(NC(=O)OCC)CCN(c3ccncc3)CC2)C(=O)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.34
HIF1A Q16665 3/20 0.34
CYP2C9 P11712 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ITGB3 P05106 2/20 0.34
ITGA2B P08514 2/20 0.34
F10 P00742 4/20 0.33
CHRM1 P11229 3/20 0.32
TSHR P16473 3/20 0.32
ATM Q13315 1/20 0.32
MAPT P10636 1/20 0.32
ALDH1A1 P00352 2/20 0.31
POLB P06746 1/20 0.31
HTT P42858 1/20 0.31
LSS P48449 1/20 0.31
GBA1 P04062 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5741473 0.94 ITGB3 (0.34) CYP2D6HIF1ACYP2C9CYP1A2CYP2C19
SCHEMBL5742122 0.93 HIF1A (0.36) CYP2D6HIF1ACYP2C9CYP1A2CYP2C19
SCHEMBL5740527 0.87 ATM (0.39) CYP2D6HIF1ACYP2C9CYP1A2CYP2C19
SCHEMBL5742755 0.83 LSS (0.44) CYP2D6HIF1ACYP2C9CYP1A2CYP2C19
SCHEMBL5741290 0.81 CYP1A2 (0.37) CYP2D6HIF1ACYP2C9CYP1A2CYP2C19
SCHEMBL5740189 0.80 SMN1; SMN2 (0.39) CYP2D6HIF1ACYP2C9CYP1A2CYP2C19
SCHEMBL5744431 0.79 F10 (0.43) F10ATMLSS
SCHEMBL5741044 0.79 F10 (0.53) F10
SCHEMBL5741976 0.79 ATM (0.37) SMN1; SMN2F10CHRM1TSHRATM
Hydrochloric Acid SCHEMBL5743334 0.79 F10 (0.43) F10ATMLSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US disclosed
EP-1340753-B1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-01-11 EP disclosed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US disclosed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof CFH, F11, F2 CYP2D6 251/4885HIF1A 491/4885CYP2C9 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.